Program will include an update on the Company’s lead asset, lanifibranor, ahead of anticipated Phase 3 NATiV3 topline results in the second half of 2026 Three renowned international experts and a ...
The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data. The recommendation was based on ...
Daix (France), New York City (New York, United States), November 28, 2025 - Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the ...
Cash and cash equivalents at €122.1 million and €24.6 million in short-term deposits2 as of June 30, 2025 Revenues of €4.5 million recorded in H1 2025 Daix (France), New York City (New York, United ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results